Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Deferred Tax (2018 - 2021)

China SXT Pharmaceuticals has reported Long-Term Deferred Tax over the past 4 years, most recently at $321444.0 for Q1 2021.

  • For Q1 2021, Long-Term Deferred Tax rose 184.87% year-over-year to $321444.0; the TTM value through Mar 2021 reached $321444.0, up 184.87%, while the annual FY2021 figure was $321444.0, 184.87% up from the prior year.
  • Long-Term Deferred Tax for Q1 2021 was $321444.0 at China SXT Pharmaceuticals, up from $23367.0 in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $321444.0 in Q1 2021 and troughed at $6174.0 in Q1 2018.
  • A 4-year average of $81667.8 and a median of $18435.5 in 2019 define the central range for Long-Term Deferred Tax.
  • On a YoY basis, Long-Term Deferred Tax climbed as much as 735.6% in 2020 and fell as far as 84.3% in 2020.
  • Year by year, Long-Term Deferred Tax stood at $6174.0 in 2018, then surged by 105.36% to $12679.0 in 2019, then surged by 84.3% to $23367.0 in 2020, then soared by 1275.63% to $321444.0 in 2021.
  • Business Quant data shows Long-Term Deferred Tax for SXTC at $321444.0 in Q1 2021, $23367.0 in Q3 2020, and $112839.0 in Q1 2020.